Dr. Denise Scots-Knight

Dr. Denise Scots-Knight

Chief Executive OfficeratMereo BioPharma Group· In proxies 2022–2023

Pay in FY2023-1% from the year before · Mereo BioPharma Group stock +208.0% the same year

Dr. Denise Scots-Knight was paid $2.2M in FY2023 (Dec), down 1%. Mereo BioPharma Group stock rose 208.0% that year.

Pay$100 in the stock at the end of FY21 → $144
Pay is from the Summary Compensation Table of each Mereo BioPharma Group proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Mereo BioPharma GroupPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role -81%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?